ICU Medical, Inc.
ICUI
Rang în acțiuni
#4033
ICU Medical, Inc., operating globally through its subsidiaries, is a medical... ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
Preț acțiune
$161.39
Capitalizare de piață
$4.04B
Schimbare (1 zi)
0.09%
Schimbare (1 an)
37.54%
Țară
US
Tranzacționează ICU Medical, Inc. (ICUI)
Categorie
Healthcare
Raport P/E pentru ICU Medical, Inc. (ICUI)
Raport P/E la data de October 2026 TTM: 135.58
Conform celor mai recente rapoarte financiare și prețului acțiunilor ICU Medical, Inc., raportul P/E actual (TTM) este 135.58. La sfârșitul anului 2023, compania avea un P/E de -81.03.
Istoricul raportului P/E pentru ICU Medical, Inc. din 2000 până în 2026
Raportul P/E la sfârșitul fiecărui an
| An | Raport P/E | Schimbă |
|---|---|---|
| 2026 (TTM) | 135.58 | -521.56% |
| 2024 | -32.16 | -60.32% |
| 2023 | -81.03 | 60.14% |
| 2022 | -50.60 | -203.68% |
| 2021 | 48.80 | -5.46% |
| 2020 | 51.62 | 35.11% |
| 2019 | 38.21 | -77.82% |
| 2018 | 172.27 | 179.12% |
| 2017 | 61.72 | 63.43% |
| 2016 | 37.76 | -4.95% |
| 2015 | 39.73 | -16.40% |
| 2014 | 47.53 | 105.27% |
| 2013 | 23.15 | 10.29% |
| 2012 | 20.99 | 50.62% |
| 2011 | 13.94 | -13.23% |
| 2010 | 16.06 | -20.47% |
| 2009 | 20.20 | 4.71% |
| 2008 | 19.29 | -13.44% |
| 2007 | 22.28 | -2.47% |
| 2006 | 22.85 | -14.46% |
| 2005 | 26.71 | -64.32% |
| 2004 | 74.86 | 253.96% |
| 2003 | 21.15 | -19.09% |
| 2002 | 26.14 | 5.58% |
| 2001 | 24.76 | 16.30% |
| 2000 | 21.29 | 0.00% |
Raportul P/E pentru companii similare sau concurenți
| Companie | P/E Ratio | Diferență P/E Ratio | Țara |
|---|---|---|---|
| 47.48 | -64.98% |
US
|
|
| 27.43 | -79.77% |
FR
|
|
| - | - |
JP
|
|
| 56.89 | -58.03% |
US
|
|
| - | - |
CH
|
Cum interpretezi un P/E ratio?
Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.
Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.
Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.